Vaccines, Blood & Biologics

KYMRIAH (tisagenlecleucel)

STN:  125646
Proper Name:  tisagenlecleucel
Tradename: KYMRIAH
Manufacturer: Novartis Pharmaceuticals Corporation
Indication:

  • Indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.

 

Page Last Updated: 09/20/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English